263 related articles for article (PubMed ID: 28453749)
1. An independently validated nomogram for individualized estimation of survival among patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825.
Gittleman H; Lim D; Kattan MW; Chakravarti A; Gilbert MR; Lassman AB; Lo SS; Machtay M; Sloan AE; Sulman EP; Tian D; Vogelbaum MA; Wang TJC; Penas-Prado M; Youssef E; Blumenthal DT; Zhang P; Mehta MP; Barnholtz-Sloan JS
Neuro Oncol; 2017 May; 19(5):669-677. PubMed ID: 28453749
[TBL] [Abstract][Full Text] [Related]
2. Independently validated sex-specific nomograms for predicting survival in patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825.
Patil N; Somasundaram E; Waite KA; Lathia JD; Machtay M; Gilbert MR; Connor JR; Rubin JB; Berens ME; Buerki RA; Choi S; Sloan AE; Penas-Prado M; Ashby LS; Blumenthal DT; Werner-Wasik M; Hunter GK; Flickinger JC; Wendland MM; Panet-Raymond V; Robins HI; Pugh SL; Mehta MP; Barnholtz-Sloan JS
J Neurooncol; 2021 Dec; 155(3):363-372. PubMed ID: 34761331
[TBL] [Abstract][Full Text] [Related]
3. An independently validated nomogram for isocitrate dehydrogenase-wild-type glioblastoma patient survival.
Gittleman H; Cioffi G; Chunduru P; Molinaro AM; Berger MS; Sloan AE; Barnholtz-Sloan JS
Neurooncol Adv; 2019; 1(1):vdz007. PubMed ID: 31608326
[TBL] [Abstract][Full Text] [Related]
4. Multi-institutional external validation of a novel glioblastoma prognostic nomogram incorporating MGMT methylation.
Molitoris JK; Rao YJ; Patel RA; Kane LT; Badiyan SN; Gittleman H; Barnholtz-Sloan JS; Bentzen SM; Kruser TJ; Huang J; Mehta MP
J Neurooncol; 2017 Sep; 134(2):331-338. PubMed ID: 28643151
[TBL] [Abstract][Full Text] [Related]
5. Validation and optimization of a web-based nomogram for predicting survival of patients with newly diagnosed glioblastoma.
Kim N; Chang JS; Wee CW; Kim IA; Chang JH; Lee HS; Kim SH; Kang SG; Kim EH; Yoon HI; Kim JW; Hong CK; Cho J; Kim E; Kim TM; Kim YJ; Park CK; Kim JW; Kim CY; Choi SH; Kim JH; Park SH; Choe G; Lee ST; Kim IH; Suh CO
Strahlenther Onkol; 2020 Jan; 196(1):58-69. PubMed ID: 31489457
[TBL] [Abstract][Full Text] [Related]
6. An independently validated survival nomogram for lower-grade glioma.
Gittleman H; Sloan AE; Barnholtz-Sloan JS
Neuro Oncol; 2020 May; 22(5):665-674. PubMed ID: 31621885
[TBL] [Abstract][Full Text] [Related]
7. Molecular-Based Recursive Partitioning Analysis Model for Glioblastoma in the Temozolomide Era: A Correlative Analysis Based on NRG Oncology RTOG 0525.
Bell EH; Pugh SL; McElroy JP; Gilbert MR; Mehta M; Klimowicz AC; Magliocco A; Bredel M; Robe P; Grosu AL; Stupp R; Curran W; Becker AP; Salavaggione AL; Barnholtz-Sloan JS; Aldape K; Blumenthal DT; Brown PD; Glass J; Souhami L; Lee RJ; Brachman D; Flickinger J; Won M; Chakravarti A
JAMA Oncol; 2017 Jun; 3(6):784-792. PubMed ID: 28097324
[TBL] [Abstract][Full Text] [Related]
8. A nomogram for individualized prediction of overall survival in patients with newly diagnosed glioblastoma: a real-world retrospective cohort study.
Kudulaiti N; Zhou Z; Luo C; Zhang J; Zhu F; Wu J
BMC Surg; 2021 May; 21(1):238. PubMed ID: 33957923
[TBL] [Abstract][Full Text] [Related]
9. A Comparative Analysis of the Usefulness of Survival Prediction Models for Patients with Glioblastoma in the Temozolomide Era: The Importance of Methylguanine Methyltransferase Promoter Methylation, Extent of Resection, and Subventricular Zone Location.
Woo P; Ho J; Lam S; Ma E; Chan D; Wong WK; Mak C; Lee M; Wong ST; Chan KY; Poon WS
World Neurosurg; 2018 Jul; 115():e375-e385. PubMed ID: 29678708
[TBL] [Abstract][Full Text] [Related]
10. A Nomogram Predicts Individual Prognosis in Patients With Newly Diagnosed Glioblastoma by Integrating the Extent of Resection of Non-Enhancing Tumors.
Zhang Z; Jin Z; Liu D; Zhang Y; Li C; Miao Y; Chi X; Feng J; Wang Y; Hao S; Ji N
Front Oncol; 2020; 10():598965. PubMed ID: 33344248
[TBL] [Abstract][Full Text] [Related]
11. Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3.
Gorlia T; van den Bent MJ; Hegi ME; Mirimanoff RO; Weller M; Cairncross JG; Eisenhauer E; Belanger K; Brandes AA; Allgeier A; Lacombe D; Stupp R
Lancet Oncol; 2008 Jan; 9(1):29-38. PubMed ID: 18082451
[TBL] [Abstract][Full Text] [Related]
12. A nomogram for individualized estimation of survival among patients with brain metastasis.
Barnholtz-Sloan JS; Yu C; Sloan AE; Vengoechea J; Wang M; Dignam JJ; Vogelbaum MA; Sperduto PW; Mehta MP; Machtay M; Kattan MW
Neuro Oncol; 2012 Jul; 14(7):910-8. PubMed ID: 22544733
[TBL] [Abstract][Full Text] [Related]
13. Short delay in initiation of radiotherapy for patients with glioblastoma-effect of concurrent chemotherapy: a secondary analysis from the NRG Oncology/Radiation Therapy Oncology Group database.
Blumenthal DT; Won M; Mehta MP; Gilbert MR; Brown PD; Bokstein F; Brachman DG; Werner-Wasik M; Hunter GK; Valeinis E; Hopkins K; Souhami L; Howard SP; Lieberman FS; Shrieve DC; Wendland MM; Robinson CG; Zhang P; Corn BW
Neuro Oncol; 2018 Jun; 20(7):966-974. PubMed ID: 29462493
[TBL] [Abstract][Full Text] [Related]
14. Radiotherapy and temozolomide for newly diagnosed glioblastoma and anaplastic astrocytoma: validation of Radiation Therapy Oncology Group-Recursive Partitioning Analysis in the IMRT and temozolomide era.
Paravati AJ; Heron DE; Landsittel D; Flickinger JC; Mintz A; Chen YF; Huq MS
J Neurooncol; 2011 Aug; 104(1):339-49. PubMed ID: 21181233
[TBL] [Abstract][Full Text] [Related]
15. Age-stratified clinical performance and survival of patients with IDH-wildtype glioblastoma homogeneously treated by radiotherapy with concomitant and maintenance temozolomide.
Berger K; Turowski B; Felsberg J; Malzkorn B; Reifenberger G; Steiger HJ; Budach W; Haussmann J; Knipps J; Rapp M; Hänggi D; Sabel M; Mijderwijk HJ; Kamp MA
J Cancer Res Clin Oncol; 2021 Jan; 147(1):253-262. PubMed ID: 32748120
[TBL] [Abstract][Full Text] [Related]
16. DGKI methylation status modulates the prognostic value of MGMT in glioblastoma patients treated with combined radio-chemotherapy with temozolomide.
Etcheverry A; Aubry M; Idbaih A; Vauleon E; Marie Y; Menei P; Boniface R; Figarella-Branger D; Karayan-Tapon L; Quillien V; Sanson M; de Tayrac M; Delattre JY; Mosser J
PLoS One; 2014; 9(9):e104455. PubMed ID: 25233099
[TBL] [Abstract][Full Text] [Related]
17. Development and Validation of Nomograms Predictive of Overall and Progression-Free Survival in Patients With Oropharyngeal Cancer.
Fakhry C; Zhang Q; Nguyen-Tân PF; Rosenthal DI; Weber RS; Lambert L; Trotti AM; Barrett WL; Thorstad WL; Jones CU; Yom SS; Wong SJ; Ridge JA; Rao SSD; Bonner JA; Vigneault E; Raben D; Kudrimoti MR; Harris J; Le QT; Gillison ML
J Clin Oncol; 2017 Dec; 35(36):4057-4065. PubMed ID: 28777690
[TBL] [Abstract][Full Text] [Related]
18. A radiomics nomogram based on multiparametric MRI might stratify glioblastoma patients according to survival.
Zhang X; Lu H; Tian Q; Feng N; Yin L; Xu X; Du P; Liu Y
Eur Radiol; 2019 Oct; 29(10):5528-5538. PubMed ID: 30847586
[TBL] [Abstract][Full Text] [Related]
19. Influence of bromodeoxyuridine radiosensitization on malignant glioma patient survival: a retrospective comparison of survival data from the Northern California Oncology Group (NCOG) and Radiation Therapy Oncology Group trials (RTOG) for glioblastoma multiforme and anaplastic astrocytoma.
Prados MD; Scott CB; Rotman M; Rubin P; Murray K; Sause W; Asbell S; Comis R; Curran W; Nelson J; Davis RL; Levin VA; Lamborn K; Phillips TL
Int J Radiat Oncol Biol Phys; 1998 Feb; 40(3):653-9. PubMed ID: 9486616
[TBL] [Abstract][Full Text] [Related]
20. A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: results of NRG Oncology RTOG 0913.
Chinnaiyan P; Won M; Wen PY; Rojiani AM; Werner-Wasik M; Shih HA; Ashby LS; Michael Yu HH; Stieber VW; Malone SC; Fiveash JB; Mohile NA; Ahluwalia MS; Wendland MM; Stella PJ; Kee AY; Mehta MP
Neuro Oncol; 2018 Apr; 20(5):666-673. PubMed ID: 29126203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
